
With the advent of targeted therapies promising to zzso the nature and success of patient care, the field of clinical zzso is facing a highly exciting zzso While much of this enthusiasm comes from the hope for improved patient zzso a review of clinical zzso rates for current therapies provides a more zzso zzso Given that the majority of patients are zzso resistant to the therapeutic potential of these zzso efforts are now directed at zzso such zzso system zzso and zzso molecular zzso Testament to this is an expanding zzso of target and zzso zzso often defined through retrospective analyses of clinical tissue and associated outcome zzso What has emerged is a complex picture, where numerous potential sources of zzso aberration can contribute to zzso zzso zzso zzso regulators and sponsors must now collaborate to determine how such knowledge should be used to enhance the clinical decision process and associated regulatory zzso 

